Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity

References

• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Jankovic R, Goncalves HJ, Cavic M, et al. LungCARD – report on worldwide research and clinical practices related to lung cancer. J BUON. 2019;24:11–19.
   PubMed Web of Science ®Google Scholar
• Cavic M, Krivokuca A, Spasic J, et al. The influence of methylenetetrahydrofolate reductase and thymidylate synthetase gene polymorphisms on lung adenocarcinoma occurrence. J BUON. 2014;19:1024–1028.
   PubMed Web of Science ®Google Scholar
• Cavic M, Spasic J, Krivokuca A, et al. TP53 and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening tool. J Clin Pathol. 2019;72:75–80.
   PubMed Web of Science ®Google Scholar
• Morgillo F, Della Corte CM, Fasano M, et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1:1–9.
   Web of Science ®Google Scholar
• Cavic M, Krivokuca A, Boljevic I, et al. Pharmacogenetics in cancer therapy – 8 years of experience at the institute for oncology and radiology of Serbia. J BUON. 2016;21:1287–1295.
   PubMed Web of Science ®Google Scholar
• Cavic M, Krivokuca A, Pavlovic M, et al. EGFR mutation testing from liquid biopsy of non-small cell lung cancer at the Institute for Oncology and Radiology of Serbia. J BUON. 2020;25(6):2635–2642.
   PubMed Web of Science ®Google Scholar
• Cavic M, Krivokuca A, Jankovic R, et al. Personalized therapy of malignant diseases. Pirot Zb Arch. 2015;40:69–79.
   Google Scholar
• Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–3334.
   PubMed Web of Science ®Google Scholar
• Han J-Y, Park K, Kim S-W, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122–1128.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
   PubMed Web of Science ®Google Scholar
• Velinovic M, Jankovic R, Jovanovic D, et al. Tumour characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid. J BUON. 2019;24:256–266.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. 2010;140:883–899.
   PubMed Web of Science ®Google Scholar
• O’Callaghan DS, O’Donnell D, O’Connell F, et al. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5:2024–2036.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Feng YC, Zhu HG, et al. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs. Med (United States). 2018;97(30):e11648.
   Google Scholar
• Aguiar-Bujanda D, Dueñas-Comino A, Saura-Grau S, et al. Neutrophil to lymphocyte ratio as a prognostic factor in European patients with epidermal growth factor receptor-mutant non-small cell lung cancer treated with tyrosine kinase inhibitors. Oncol Res Treat. 2018;41:755–760.
   PubMed Web of Science ®Google Scholar
• Chen YM, Lai CH, Chang HC, et al. Baseline and trend of lymphocyte-to-monocyte ratio as prognostic factors in epidermal growth factor receptor mutant non-small cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors. PLoS One. 2015;10:1–13.
   Web of Science ®Google Scholar
• Wang L, Liang D, Xu X, et al. The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer. Oncol Lett. 2017;14:6449–6456.
   PubMed Web of Science ®Google Scholar
• Gu X, Sun S, Gao XS, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep. 2016;6:1–7.
   PubMed Web of Science ®Google Scholar
• Inokuchi H, Okano K, Kawamura A, et al. Prognostic value of neutrophil-to-lymphocyte ratio before cranial radiotherapy in non-small cell lung cancer patients with limited brain metastases: a propensity-score matched pair comparison of whole-brain radiotherapy and stereotactic irradiation alone. Int J Radiat Oncol. 2019;105:E78–E79.
   Google Scholar
• Russo A, Franchina T, Ricciardi GRR, et al. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. J Cell Physiol. 2018;233:6337–6343.
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33:e22964.
   PubMed Web of Science ®Google Scholar
• Phan TT, Ho TT, Nguyen HT, et al. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. Int J Gen Med. 2018;11:423–430.
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203.
   PubMed Web of Science ®Google Scholar
• Serbia M of H of the R of. National guidelines of good clinical practice for the diagnostics and treatment of lung cancer 2012 [Internet]. Serbia; 2012 [cited 2021 Feb 12]. Available from: https://www.zdravlje.gov.rs/view_file.php?file_id=672&cache=sr
   Google Scholar
• Cavic M, Krivokuca A, Boljevic I, et al. Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals. Expert Rev Mol Diagn. 2020 Dec 21;1–7. DOI:10.1080/14737159.2021.1860760
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet]. [ cited 2021 Feb 12] Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
   Google Scholar
• Gahr S, Stoehr R, Geissinger E, et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer. 2013;109:1821–1828.
   PubMed Web of Science ®Google Scholar
• Tong Y-S, Tan J, Zhou X-L, et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017;15:221.
   PubMed Web of Science ®Google Scholar
• Deng C, Zhang N, Wang Y, et al. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. Medicine (Baltimore). 2019;98:e16875.
   PubMed Web of Science ®Google Scholar
• Drpa G, Sutic M, Baranasic J, et al. Neutrophil-to-lymphocyte ratio can predict outcome in extensive-stage small cell lung cancer. Radiol Oncol. 2020;54:437–446.
   PubMed Web of Science ®Google Scholar
• Sim SH, Beom SH, Ahn YO, et al. Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors. Thorac Cancer. 2016;7:161–166.
   PubMed Web of Science ®Google Scholar
• Lim JU, Yeo CD, Kang HS, et al. Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion. Sci Rep. 2019;9:1–8.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20:485–503.
   PubMed Web of Science ®Google Scholar
• Kiss M, Caro AA, Raes G, et al. Systemic reprogramming of monocytes in cancer. Front Oncol. 2020;10:1399.
   PubMed Web of Science ®Google Scholar
• Jeong J, Suh Y, Jung K. Context drives diversification of monocytes and neutrophils in orchestrating the tumour microenvironment. Front Immunol. 2019;10:1817.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Yasumoto A, Amano Y, et al. Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor. PLoS One. 2018;13:e0203625.
   PubMed Web of Science ®Google Scholar
• Chen Y-M, Lai C-H, Chang H-C, et al. Baseline and trend of lymphocyte-to-monocyte ratio as prognostic factors in epidermal growth factor receptor mutant non-small cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors. PLoS One. 2015;10(8):e0136252.
   PubMed Web of Science ®Google Scholar
• Lan H, Zhou L, Chi D, et al. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: a single institutional cohort study. Oncotarget. 2017;8:35301–35310.
   PubMedGoogle Scholar
• Chen Y-M, Lai C-H, Rau K-M, et al. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer. 2016;16:868.
   PubMed Web of Science ®Google Scholar
• Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells. 2020;9:855.
   Web of Science ®Google Scholar
• Pavan A, Calvetti L, Dal Maso A, et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist. 2019;24:1128–1136.
   PubMed Web of Science ®Google Scholar